| 臺大學術典藏 |
2022-08-19T06:48:40Z |
Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma
|
Shao Y.-Y.; Kuo H.-Y.; Jeng Y.-M.; Wu Y.-M.; Wang H.-P.; Hsu C.; CHIH-HUNG HSU; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-12T06:28:23Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma
|
Hsu C.; Huang C.-S.; Chao T.-Y.; Lu Y.-S.; Bu C.-F.; Chen M.M.; KING-JEN CHANG; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-12T06:27:55Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Shao Y.-Y.; Kuo K.-T.; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; KING-JEN CHANG; Lin C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-07-26T08:55:57Z |
Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma
|
Shao Y.-Y.; Kuo H.-Y.; YUNG-MING JENG; Wu Y.-M.; Wang H.-P.; Hsu C.; Hsu C.-H.; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
| 國家衛生研究院 |
2022-07 |
Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors
|
Su, YY;Lee, WH;Wang, JH;Wang, HW;Chen, TW;Chen, BB;Ho, HJ;Liu, TH;Chou, SC;Chen, BR;Liu, TW;Chen, LT;Wu, CY;Hsu, C |
| 臺大學術典藏 |
2022-06-27T07:07:53Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; CHONG-JEN YU; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-27T07:06:40Z |
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
|
Kuo S.-H.; Yang C.-H.; CHONG-JEN YU; Hsu C.; Cheng A.-L.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:06:37Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.; Yang C.-H.; CHONG-JEN YU; Shih J.-Y.; Hsu C.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:06:33Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Yang C.-H.; Shih J.-Y.; Chen K.-C.; CHONG-JEN YU; Yang T.-Y.; Lin C.-P.; Su W.-P.; Gow C.-H.; Hsu C.; Chang G.-C.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:06:23Z |
Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers
|
Chen J.-P.; Lo Y.; CHONG-JEN YU; Hsu C.; Shih J.-Y.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-27T07:06:22Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; CHONG-JEN YU; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-10T06:11:16Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
ZHONG-ZHE LIN; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-10T06:11:14Z |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
ZHONG-ZHE LIN; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:14Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; ZHONG-ZHE LIN; Chang M.-C.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:13Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.; Shen Y.-C.; ZHONG-ZHE LIN; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:12Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:11Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:10Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; ZHONG-ZHE LIN; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:09Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:08Z |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; ZHONG-ZHE LIN; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2022-06-10T06:11:08Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
ZHONG-ZHE LIN; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:07Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:06Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; ZHONG-ZHE LIN |
| 臺大學術典藏 |
2022-06-10T06:11:05Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
ZHONG-ZHE LIN; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2022-06-10T06:11:05Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; ZHONG-ZHE LIN; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L. |
